<DOC>
	<DOC>NCT01272323</DOC>
	<brief_summary>Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to cat dander in the EEC among subjects who completed all dosing visits in study CP005 approximately one year after the start of treatment.</brief_summary>
	<brief_title>Cat-PAD Follow on Study</brief_title>
	<detailed_description>Subjects who completed all dosing visits and the post treatment challenge (PTC) in study CP005 will be invited to attend the Screening Visit for CP005A. Subjects will attend for 4 visits to the EEC on successive days. Following the last EEC visit a follow-up visit will be performed 3-10 days later.</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Inclusion Criteria Previously randomised in study CP005, completed all treatment visits and the Post Treatment Challenge (PTC). Exclusion Criteria "Partly controlled" and "uncontrolled" asthma History of anaphylaxis to cat allergen FEV1 of less than 70% of predicted Subjects who cannot tolerate baseline challenge in the EEC Treatment with betablockers,Alphaadrenoceptor blockers, Tranquillizers or psychoactive drugs A history of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Cat allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
</DOC>